First Horizon National Corporation (NYSE:FHN)
First Horizon National Corporation (NYSE:FHN) represented a move of -3.23 percent or $0.5 per share and closed its previous day trading session at $14.97. 3.69 Million Shares were traded in the last trading session with an Average Volume of 3.26 Million Shares. The stock currently has a Market Capitalization of 4.96 Billion.
The First Horizon National family of companies provides financial services to individual and business customers through: First Horizon Home Loans, FTN Financial, First Tennessee Bank, and First Horizon Merchant Services.
The stock traded between $14.94 and $20.86 over 1-Year time period showing its price to sales ratio of 3.46. First Horizon National Corporation (NYSE:FHN) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-15.13 and 200-Day Simple Moving Average of $-19.58. Its Price to Free Cash Flow is 0 and Price to Book of 1.17.
Analyst’s recommended the stock as 2.2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, First Horizon National Corporation (NYSE:FHN) reported its Actual EPS of $0.36/share. The analysts offering Earnings Estimates for the company were believing that First Horizon National Corporation could bring EPS of $0.36/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus showing an Earnings Surprise of 0 Percent.
vTv Therapeutics Inc. (NASDAQ:VTVT)
In the last trading session, vTv Therapeutics Inc. (NASDAQ:VTVT) added its value by -5.96% closing at the price of $3.47. The stock currently has market capitalization of 107.36 Million, with average volume of 2.8 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently vTv Therapeutics Inc. (NASDAQ:VTVT) is showing beta of 0. This particular value of beta suggests that vTv Therapeutics Inc. (NASDAQ:VTVT) has historically moved 0% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for vTv Therapeutics Inc. (NASDAQ:VTVT) is at $-0.83.
The stock currently has RSI of 62.12. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.
vTv Therapeutics Inc. (NASDAQ:VTVT) topped its 52-week high price of $8.40 on 01/31/18 and 52-Week Low Price of $0.65 on 04/11/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 17.74% and monthly volatility of 30.93% respectively.